WHOOP Podcast Inside the Ethics of Biological Aging with Dr. Raiany Romanni-Klein
36 snips
Feb 18, 2026 Dr. Raiany Romanni-Klein, a researcher, philosopher, and bioethicist focused on longevity and policy. She discusses why aging may be an underfunded driver of suffering. Short takes cover ethics of treating aging as a solvable problem, policy and incentive barriers to longevity trials, why brain health yields high ROI, and the role of exercise, diet, pharma, and biomarkers.
AI Snips
Chapters
Books
Transcript
Episode notes
Invest In Existing Humans, Not Just Birth Rates
- Investing in existing adults can boost productivity and fertility without forgoing higher birth rates.
- Delaying menopause or improving adult healthspan can simultaneously improve mortality, productivity, and fertility.
Biomarkers Are The Missing Trial Endpoint
- We lack robust, validated biomarkers to measure biological age and short-term trial endpoints.
- XPRIZE milestones aimed to spur biomarker validation before declaring a grand prize for age reversal.
Market Incentives Favor Disease Targets
- Free markets favor treatments with clear disease endpoints and faster regulatory paths over broad healthspan drugs.
- That incentive structure explains why pharma targets measurable diseases rather than fuzzy aging outcomes.
